Virtus Advisers LLC Takes $487,000 Position in Sarepta Therapeutics, Inc. $SRPT

Virtus Advisers LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 27,098 shares of the biotechnology company’s stock, valued at approximately $487,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in Sarepta Therapeutics in the fourth quarter valued at $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth about $25,000. Meeder Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Ancora Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Allworth Financial LP boosted its position in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SRPT shares. Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, July 9th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $25.06.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $19.22 on Friday. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $17.35 and its 200 day moving average price is $18.30. Sarepta Therapeutics, Inc. has a 52 week low of $14.68 and a 52 week high of $25.32. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -6.63, a PEG ratio of 0.29 and a beta of 0.23.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. During the same period in the previous year, the firm posted $2.02 EPS. The company’s quarterly revenue was down 34.3% compared to the same quarter last year. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.